When was PathogenDX founded?

PathogenDX was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is PathogenDX located?

PathogenDX is headquartered in Tucson, United States. It is registered at 9375 E. Shea Blvd, Suite 100, Scottsdale, Arizona 85260.

Who is the current CEO of PathogenDX?

Milan Patel of PathogenDX. They have also founded 1 company and are angel investors in 15 startups, including .

How many employees does PathogenDX have?

As of Aug 31, 2026, the latest employee count at PathogenDX is 28.

Is PathogenDX a funded company?

PathogenDX is a funded company, having raised a total of $11.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 19, 2016.

When was the latest funding round of PathogenDX?

PathogenDX's latest funding was a $***** Grant (prize money) round on Aug 17, 2020, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.31B in funding in 2026 to date.

Where does PathogenDX rank among its competitors?

PathogenDX ranks 2nd amongst 87 active competitors, of which 16 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was KromaTiD, which secured $8M in Jul, 2025.

Who are the top competitors of PathogenDX?

PathogenDX's top competitors include Inflammatix, Agendia and InDevR. Among them, KromaTiD secured the most recent funding round in July, 2025.

PathogenDX - 2026 Company Profile, Team, Funding & Competitors

Company Details

PathogenDX provides DNA-based pathogen testing kits. They offer Delivering Disruptive Testing Technology to the botanicals, food, and agriculture industries. The company focuses on food and agricultural microbial testing, cannabis testing, and botanical testing.

Website: pathogendx.com
Social
Email ID: *****@pathogendx.com
Phone Number: +1 **********
Registered Address: 9375 E. Shea Blvd, Suite 100, Scottsdale, Arizona 85260

Key Metrics

Founded Year

2014

Location

Tucson, United States

Stage

Series B

Total Funding

$11.6M in 5 rounds

Latest Funding Round

Grant (prize money), Aug 17, 2020, $*****

Investors

Entourage Effect Capital & 12 more

Ranked

2^nd among 87 active competitors

Employee Count

28 as on Aug 31, 2026

Similar Companies

Inflammatix & 122 more

View PathogenDX's full profile

PathogenDX is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Pathogendx, Inc CIN: 47-2362135 , United States, Active	Nov 23, 2014	-	31 (As on Dec 31, 2021)	-

PathogenDX has raised a total funding of $11.6M over 5 rounds. Its first funding round was on Apr 19, 2016. Its latest funding round was a Grant (prize money) round on Aug 17, 2020 for $*****. 1 investor participated in its latest round. PathogenDX has 13 institutional investors.

Here is the list of recent funding rounds of PathogenDX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 17, 2020	2549373	Grant (prize money)	3953431	7056267	3482199	5768899
Aug 11, 2020	1894564	Grant (prize money)	9225933	5809284	1370216	HHS
Sep 30, 2019	5974446	Series B	3419441	2634420	Entourage Effect Capital	Altitude Investment Management & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of PathogenDX's funding rounds and investors

The founders of PathogenDX are Milan Patel and Michael Hogan. Milan Patel is the CEO of PathogenDX.

Here are the details of PathogenDX's key team members:

Milan Patel: CEO and Co-Founder of PathogenDX. They are also an angel investor in 15 startups.
Contact Info: 1 email address and 1 phone number
Michael Hogan: Co-Founder & CSO of PathogenDX.
Contact Info: 1 email address

View details of PathogenDX's Founder profiles and Board Members

PathogenDX's employee count trend

PathogenDX has 28 employees as of Aug 26. Here is PathogenDX's employee count trend over the years:

Uncover PathogenDX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PathogenDX include Inflammatix, Agendia and InDevR. Here is the list of Top 10 competitors of PathogenDX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	64/100
2nd	PathogenDX 2014, Tucson (United States), Series B	Provider of DNA-based pathogen testing kits	$11.6M	Altitude Investment Management, GROWNEXOTICSCANNABIS ... & 11 others	61/100
3rd	Agendia 2003, Irvine (United States), Series F	Provider of genomic diagnostic products for the treatment of cancer	$123M	Athyrium Capital Management, Van Herk Groep ... & 9 others	59/100
4th	InDevR 2003, Boulder (United States), Acquired	Manufacturer of biotherapeutics, vaccines and diagnostic products	$16M	Adjuvant Capital, BioMerieux & 2 others	57/100
5th	KromaTiD 2007, Fort Collins (United States), Series C	Provider of molecular and genetic tests for detection of disease-causing mutations	$15.4M	Broadoak Capital Partners, First Capital Ventures ... & 5 others	55/100
6th	Akonni 2003, Frederick (United States), Series C	Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification	$39.7M	Righton, Choosemaryland.org & 5 others	49/100
7th	GenomeDx Biosciences 2008, San Diego (United States), Series C	Genomic tests for urologic cancers	$69.7M	Merck Global Health Innovation Fund, Calibrium ... & 6 others	46/100
8th	PamGene 1999, Virginia (United States), Series B	Provider of a microarray platform and gene expression profiling system for post-genomic applications	$17.9M	Life Sciences Partners, EQT & 6 others	43/100
9th	BioArray Solutions 2001, New York City (United States), Acquired	Beadchip for biomolecular analysis	$56.8M	Axiom Venture Partners, NGN Capital	42/100
10th	Exiqon 1995, Vedbaek (Denmark), Acquired	Develops LNA-based tools for diagnostics and research	$22.9M	Danske Bank, Teknoinvest & 1 others	41/100